Private credit funds' exposure to software has come back to bite them, presenting new risks and opportunities for banks. ...

Massachusetts-based Revvity, Inc. (RVTY) is a global life sciences and diagnostics company that provides instruments, reagents, software, and services to support drug discovery, clinical research, and medical diagnostics. Valued at $9.5 billion by market cap, the company focuses on translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection, diagnosis, informatics, and other areas. Companies worth $10 billion or more are generally described as “large-cap st ...

Mr. Beighton Brings Demand-Side Perspective to Accelerate Kornit’s On-Demand Digital Production StrategyROSH-HA'AYIN, Israel, March 19, 2026 (GLOBE NEWSWIRE) -- Kornit Digital LTD. (NASDAQ: KRNT) ("Kornit" or the "Company"), a global leader in sustainable, on-demand digital fashion and textile production technologies, today announced it has appointed Nick Beighton, former Chief Executive Officer of ASOS, as a strategic advisor to the Company and its Board of Directors. His appointment reflects Kornit’s cont ...

Dover Corporation (NYSE:DOV) is included among the 14 High Growth Dividend Paying Stocks to Invest in Now. Wells Fargo Sees Dover (DOV) Positioned for Outperformance in Expanding Cycle Image by Alexsander-777 from Pixabay On March 17, Wells Fargo analyst Joseph O’Dea upgraded Dover Corporation (NYSE:DOV) to Overweight from Equal Weight. It also raised the price target on the stock to $230 from $210. The firm pointed to supportive US macro data, which it believes is helping drive a recovery in short-cycl ...

The shares of Palantir Technologies Inc (NASDAQ:PLTR) are 1.1% lower to trade at $153.35 at last check, brushing off a price-target hike to $200 from $180 at UBS. Despite a 14% deficit in 2026, the software stock sports an 83.5% year-over-year lead and has recently cleared a trendline with bullish implications. The trendline in question is the stock's 50-day moving average. Per Schaeffer's Senior Quantitative Analyst Rocky White, this “crossover” event happened seven other times in  the last 10 years, after ...

Core Insights - Diamond Hill Capital's "Mid Strategy" reported a strong performance in Q4 2025, with a return of 3.65% compared to the Russell Midcap Index's 0.16% [1] - The strategy achieved a year-to-date return of 13.47%, outperforming the Russell Midcap Index's 10.60% [1] - AI-related spending was a significant driver in equity markets, although investor caution emerged in December [1] Company Highlights - Ciena Corporation (NYSE:CIEN) was identified as a leading contributor to the Diamond Hill Mid Strategy, benefiting from increased demand related to hyperscalers and AI [2][3] - Ciena's stock closed at $370.05 on March 17, 2026, with a one-month return of 19.00% and a remarkable 461.53% increase over the past 52 weeks [2] - The company reported record revenue of $1.43 billion in Q1 of fiscal 2026, reflecting strong business execution [3] Market Position - Ciena Corporation has a market capitalization of $52.349 billion, indicating its significant presence in the network technology sector [2] - Despite its strong performance, Ciena is not among the 40 most popular stocks among hedge funds heading into 2026, with 71 hedge fund portfolios holding its stock at the end of Q4 [3] - The company is positioned to benefit from growing cloud spending, particularly in its pluggables and data interconnect business [3]

Core Insights - Oracle's international revenue performance is crucial for assessing its financial resilience and growth prospects [1][2] Group 1: International Revenue Performance - For the quarter ending February 2026, Oracle's total revenue reached $17.19 billion, marking a year-over-year increase of 21.7% [4] - Revenue from Europe, Middle East, and Africa was $3.96 billion, accounting for 23.1% of total revenue, which was a slight miss compared to the consensus estimate of $4.01 billion [5] - Asia-Pacific contributed $1.87 billion, or 10.9% of total revenue, also falling short of the expected $1.96 billion [6] Group 2: Future Projections - Analysts project Oracle's total revenue for the current fiscal quarter to be $19.07 billion, reflecting a 19.9% increase from the same quarter last year [7] - For the full year, total revenue is expected to reach $67.07 billion, representing a 16.9% increase from the previous year [8] - Revenue contributions from Europe, Middle East, and Africa, and Asia-Pacific are anticipated to be $15.75 billion (23.5%) and $7.77 billion (11.6%), respectively [8] Group 3: Market Dynamics - Oracle's reliance on international markets presents both opportunities and challenges, necessitating close monitoring of international revenue trends for accurate future projections [9] - The interconnected global economy and geopolitical factors significantly influence earnings estimations for companies like Oracle [10]

Company Overview - IDEXX Laboratories, Inc. is a leader in veterinary diagnostics, software, and water testing solutions, based in Westbrook, Maine, with a market cap of $45.7 billion [1] - The company develops diagnostic instruments, test kits, software, and laboratory services for veterinarians, farmers, and laboratories to monitor animal health and detect diseases [1] Market Position - IDEXX is classified as a "large-cap stock" and is recognized as a market leader in veterinary diagnostics, benefiting from strong brand recognition and a large installed base of diagnostic instruments [2] - The company's solutions are utilized in over 175 countries, indicating a robust global presence [2] Stock Performance - Shares of IDEXX have decreased by 25.5% from their 52-week high of $769.98 and have dipped 18.5% over the past three months, underperforming the S&P 500 Index's decline of 2.9% [3] - Over the past six months, IDEXX shares are down 10.5%, while the S&P 500 has shown marginal returns [5] - Despite recent declines, IDEXX stock has increased by 41.2% over the past 52 weeks, outperforming the S&P 500's 20.1% increase during the same period [5] Recent Financial Performance - On February 2, IDEXX reported a strong fourth-quarter 2025 performance with revenue of $1.1 billion and adjusted earnings of $3.08 per share, both exceeding analyst expectations [6] - However, the gross margin of 60.3% fell short of the consensus forecast of 61% [6] Competitive Landscape - IDEXX has outperformed its main competitor, Zoetis Inc., which has seen a decline of 27.8% over the past 52 weeks and 22% over the past six months [7] - Analysts maintain a cautiously optimistic outlook for IDEXX, with a consensus rating of "Moderate Buy" and a mean price target of $773.58, representing a 34.8% premium to current levels [7]

Core Insights - Thermo Fisher Scientific Inc. is recognized as one of Goldman Sachs' top healthcare stocks, with a strong strategic outlook presented by CEO Marc Casper at the 47th Annual Raymond James Institutional Investor Conference [1]. Group 1: Growth Prospects - The company is positioned to achieve a growth rate of 3% to 4% by 2026, building on a 2% organic growth from the previous year and targeting a long-term expansion rate of 5% to 6% [3]. - Growth will be driven by the integration of AI to enhance operations and capitalize on market opportunities, alongside a focus on mergers and acquisitions to strengthen the core business [3][4]. Group 2: Acquisition Strategy - Thermo Fisher is in the process of completing the acquisition of Olink, which is expected to enhance its endpoint solution capabilities [4]. - The company is also targeting additional acquisitions aimed at delivering high value to customers and generating strong returns [4]. Group 3: Market Position - Thermo Fisher Scientific is a global leader in serving science, providing over 2 million products and services across pharmaceutical development, biotechnology research, clinical diagnostics, and laboratory management [5].

Core Viewpoint - Stem, Inc. is facing challenges in its software sales outlook, leading to a reduction in price target by UBS despite improvements in its software revenue mix and EBITDA performance [2][3][4]. Financial Performance - For Q4 2025, Stem reported revenue of $47.2 million, a decrease of 15% year-over-year, primarily due to lower battery hardware sales [3]. - Software, services, and edge hardware revenue increased by 62% to $46.5 million in Q4 2025 [3]. - The non-GAAP gross margin improved to 45% from 36%, and adjusted EBITDA rose to $5.5 million from $4.2 million [3]. - The net loss narrowed to $16.0 million from $51.1 million in the previous year [3]. Annual Performance - For the full year 2025, Stem's revenue increased by 8% to $156.3 million [4]. - Revenue from software, services, and edge hardware climbed by 25% to $141.4 million [4]. - The company achieved an adjusted EBITDA of $6.7 million, a significant improvement from a loss of $22.8 million in 2024 [4]. - At the end of Q4 2025, Stem had $48.9 million in cash and cash equivalents [4]. Market Position - Stem, Inc. provides software, services, and energy management technology for clean energy assets, enabling customers to monitor, optimize, and operate various energy systems globally [5].